Launched to develop a better bifurcated stent, Stentys discovered its device appears to be effective in treating a larger unmet clinical need: AMI. This strategy shift holds great promise, but the com
The architect of J&J’s cardiology business reflects on the ups and downs of building a stent business, integrating a hostile takeover, and why—despite all their success—stents have not met their origi
Headed by the team that pioneered the coronary stent, Prescient is using a medical imaging breakthrough and a unique financing strategy to succeed where other device companies have failed: detecting a